Gado, M., Fathi, M., Khalifa, N., Al-Mokadem, S., El- Ganiny, I. (2021). Role of Interleukin 33 in Immune Response Process of Vitiligo Disease. The Egyptian Journal of Hospital Medicine, 85(1), 3483-3486. doi: 10.21608/ejhm.2021.199720
Mariam Nasr Gado; Marwa Mohamed Fathi; Naglaa Ali Khalifa; Sahar Mohamed Al-Mokadem; Ibrahim El-Gharib El- Ganiny. "Role of Interleukin 33 in Immune Response Process of Vitiligo Disease". The Egyptian Journal of Hospital Medicine, 85, 1, 2021, 3483-3486. doi: 10.21608/ejhm.2021.199720
Gado, M., Fathi, M., Khalifa, N., Al-Mokadem, S., El- Ganiny, I. (2021). 'Role of Interleukin 33 in Immune Response Process of Vitiligo Disease', The Egyptian Journal of Hospital Medicine, 85(1), pp. 3483-3486. doi: 10.21608/ejhm.2021.199720
Gado, M., Fathi, M., Khalifa, N., Al-Mokadem, S., El- Ganiny, I. Role of Interleukin 33 in Immune Response Process of Vitiligo Disease. The Egyptian Journal of Hospital Medicine, 2021; 85(1): 3483-3486. doi: 10.21608/ejhm.2021.199720
Role of Interleukin 33 in Immune Response Process of Vitiligo Disease
Background: When melanocytes cease to operate, vitiligo develops. It is a skin and mucosa depigmentation condition. Any area of the body can develop well-circumscribed white macules or patches in this disease. Approximately 1-2 percent of the population is affected by Vitiligo. Suppression of tumorigenicity 2 (ST2), a newly discovered member of the interleukin-1 (IL-1) family, acts as a receptor for the IL-1 receptor-like 1 protein (also known as IL-1RL1) while also acting as a ligand for the interleukin-1 receptor-like 1 protein (also known as IL-1RL1) and suppressing tumorigenicity 2. Objective: To study Interleukin 33 (IL-33) in generalized and localized vitiligo patients and to assess their relationship with disease activity. Conclusion: Vitiligo could be associated with increased serum levels of IL-33, which could help as predictor marker of disease activity in vitiligo.